Abraxis backs SPARC as prognostic biomarker

Elevating Community Oncology Care: Insights From World GU 2025

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

Related Content

Elevating Community Oncology Care: Insights From World GU 2025

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.